Vertex Pharmaceuticals Inc. | |
Stock Exchange | Frankfurt Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
255.56 M |
Public Float |
226.28 M |
Vertex Pharmaceuticals Inc. | |
Stock Exchange | Mexican Stock Exchange |
EPS |
- |
Market Cap |
- |
Shares Outstanding |
255.56 M |
Public Float |
226.28 M |
Vertex Pharmaceuticals Inc. | |
Stock Exchange | NASDAQ Stock Market |
EPS |
$8.3 |
Market Cap |
$45.68 B |
Shares Outstanding |
256.12 M |
Public Float |
255.16 M |
Address |
50 Northern Avenue Boston Massachusetts 02210 United States |
Employees | - |
Website | http://www.vrtx.com |
Updated | 07/08/2019 |
Vertex Pharmaceuticals, Inc. engages in the business of discovering, developing, manufacturing and commercializing small molecule drugs for patients with serious diseases. It focuses on development and commercializing therapies for the treatment of cystic fibrosis; infectious diseases, including viral infections, such as influenza, and bacterial infections; autoimmune diseases, such as rheumatoid arthritis; cancer, inflammatory bowel disease; and neurological disorders, including pain, Huntington's disease and multiple sclerosis. The company was founded by Joshua S. |